PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
-6.92%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
121.05%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
121.15%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
115.11%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.25%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
42.15%
Diluted share count expanding well above GNPX's 80.76%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-8.23%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-717224.10%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12351.82%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
45138.86%
Net income/share CAGR above 1.5x GNPX's 99.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
41496.01%
5Y net income/share CAGR above 1.5x GNPX's 96.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
7331.25%
3Y net income/share CAGR above 1.5x GNPX's 96.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
8529.17%
Equity/share CAGR of 8529.17% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2357.47%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
2495.43%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
131.44%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
-41.82%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.65%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
44.07%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.